Acro Biomedical (ACBM) Receivables (2021 - 2023)

Acro Biomedical has reported Receivables for 3 years, with the latest figure at $498500.0 in Q2 2023.

• On a quarterly basis, Receivables rose 67.0% year-over-year to $498500.0 in Q2 2023; TTM through Jun 2023 was $498500.0, a 67.0% increase from a year earlier, with the FY2022 full-year figure at $638500.0, up 6.77% from the prior year.
• Receivables was $498500.0 for Q2 2023 at Acro Biomedical, down from $608500.0 in the prior quarter.
• The five-year high for Receivables was $638500.0 in Q4 2022, with the low at $278500.0 in Q3 2022.
• Average Receivables over 3 years is $459857.1, with a median of $498500.0 recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Receivables gained 6.77% in 2022, then soared 103.85% in 2023.
• Over 3 years, Receivables stood at $598000.0 in 2021, then increased by 6.77% to $638500.0 in 2022, then fell by 21.93% to $498500.0 in 2023.
• The last three Receivables figures came in at $498500.0 (Q2 2023), $608500.0 (Q1 2023), and $638500.0 (Q4 2022), per Business Quant data.